Drug Profile
GSK 2241658A
Alternative Names: 2241658A; GSK 2241658A Antigen-Specific Cancer Immunotherapeutic; GSK 2241658A ASCI; GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic; GSK2241658A; NY-ESO-1 Antigen Specific Cancer ImmunotherapeuticLatest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 May 2020 No recent reports of development identified for phase-I development in Malignant-melanoma(Inoperable/Unresectable, Metastatic disease) in Australia (IM, Injection)
- 28 May 2020 No recent reports of development identified for phase-I development in Malignant-melanoma(Inoperable/Unresectable, Metastatic disease) in Austria (IM, Injection)
- 28 May 2020 No recent reports of development identified for phase-I development in Malignant-melanoma(Inoperable/Unresectable, Metastatic disease) in France (IM, Injection)